Maxim Group resumed coverage on Heat Biologics with a new price target
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group resumed coverage of Heat Biologics with a rating of Buy and set a new price target of $14.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk's Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulator
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company's evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May
DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian
Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight and set a new price target of $22.00
Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight
Alliance Global Partners reiterated coverage of Heat Biologics with a rating of Buy and set a new price target of $40.00 from $5.00 previously
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company's Biothreat Advisory Board and as a senior advisor to the Company. Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation's premier medical materiel prepared
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Dr. Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer. Dr. Tebbey's research, development and commercial launch experiences include novel monoclonal antibodies
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics' product portfolio. Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at M
SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)
SC 13D/A - HEAT BIOLOGICS, INC. (0001476963) (Subject)
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk
DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effec
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company's activities. The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company's website at https://ir.heatbio.com/. An audio replay of the call will be available th